Letermovir
FDA-approved product (tablet, oral), marketed as Prevymis.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cytomegalovirus infection
- Infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antivirals
- FDA pharmacologic class
- Cytomegalovirus DNA Terminase Complex Inhibitor FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX18
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Letermovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
NCT03930615 · start 2019-06-21
Registered record
- Registry ID
- NCT03930615
- Conditions
- Cytomegalovirus Infection
- Interventions
- Letermovir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-06-21
- Completion
- 2022-03-16
- Enrolment
- 220
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCytomegalovirus InfectionInterventionLetermovir; PlaceboPhasePhase 3Registry statusCompletedLetermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
NCT03728426 · start 2019-01-11
Registered record
- Registry ID
- NCT03728426
- Conditions
- Cytomegalovirus Infections
- Interventions
- Letermovir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2019-01-11
- Completion
- 2022-03-28
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCytomegalovirus InfectionsInterventionLetermovirPhasePhase 2Registry statusCompletedLetermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
NCT03443869 · start 2018-05-03
Registered record
- Registry ID
- NCT03443869
- Conditions
- CMV Disease
- Interventions
- Letermovir; Valganciclovir; Acyclovir (ACV); Placebo to ACV; Placebo to LET; Placebo to VGCV
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-05-03
- Completion
- 2022-04-05
- Enrolment
- 601
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCMV DiseaseInterventionLetermovir; Valganciclovir; Acyclovir (ACV); Placebo to ACV +2 morePhasePhase 3Registry statusCompletedLetermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
NCT02137772 · start 2014-06-06
Registered record
- Registry ID
- NCT02137772
- Conditions
- Prevention of CMV Infection or Disease
- Interventions
- Letermovir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-06-06
- Completion
- 2016-11-21
- Enrolment
- 570
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrevention of CMV Infection or DiseaseInterventionLetermovir; PlaceboPhasePhase 3Registry statusCompletedSafety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
NCT01063829 · start 2010-03
Registered record
- Registry ID
- NCT01063829
- Conditions
- HCMV Reactivation or HCMV End-Organ Disease
- Interventions
- 60 mg AIC246; 120 mg AIC246; 240 mg AIC246; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2011-12
- Enrolment
- 133
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHCMV Reactivation or HCMV End-Organ DiseaseIntervention60 mg AIC246; 120 mg AIC246; 240 mg AIC246; PlaceboPhasePhase 2Registry statusCompleted